NCT00402441View on ClinicalTrials.gov

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

PHASE4CompletedINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

Risedronate (HMR4003)

Trial Locations (1)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Procter and Gamble

INDUSTRY

lead

Sanofi

INDUSTRY